NICE jury still out on Takeda's Daxas without further trial
This article was originally published in Scrip
Executive Summary
Takeda will have to conduct another clinical trial if it wants to convince NICE, the health technology appraisal institute for England and Wales, to recommend its chronic obstructive pulmonary disease (COPD) drug Daxas (roflumilast) , according to the institute's final guidance.